AzTrials
AzTrials

Plasmablastic LymphomaPhase 2FIL_DALYANCT04915248

Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.

A Phase 2 study testing Daratumumab, Bortezomib and Dexamethasone in people with Plasmablastic Lymphoma, run by Fondazione Italiana Linfomi - ETS at 18 sites in Italy.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

It is an open-label, multicenter, phase II, single arm trial to Evaluate Activity and Safety of Daratumumab in combination with Bortezomib and Dexamethasone in patients about 28 patients with Relapsed or Refractory Plasmablastic lymphoma. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Plasmablastic Lymphoma
What is being tested?
Daratumumab, Bortezomib and Dexamethasone
Could I receive a placebo?
No, everyone receives an active treatment
How many people
28 participants
Where
18 sitesItaly
Study dates
11 Jul 2022to 1 Jul 2027
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Histologically confirmed plasmablastic lymphoma according to WHO 2017, CD38-positive by immunohistochemistry (≥5% of positive cells) Local diagnosis of PBL and local CD38 assessment ≥5% will suffice for enrollment and start of treatment.
  • Patients with plasmablastic lymphoma relapsed or refractory:
  • after at least one line of conventional-dose chemotherapy followed or not by autologous stem cell transplantation;
  • after at least one line of conventional-dose chemotherapy and not eligible for salvage autologous or allogeneic transplantation;
  • ECOG Performance Status ≤ 3;
  • Age ≥ 18 years;
Show all 15Show fewer
  • Both HIV-negative and HIV-positive patients are eligible;
  • HIV infection responsive to ongoing cART (combination antiretroviral therapy);
  • At least one measurable disease lesion identifiable by imaging:
  • A nodal lesion must be at least 11 mm x 11 mm OR ≥ 16 mm in the greatest transverse diameter (regardless of short axis measurement).
  • An extranodal lesion must be at least 10 mm x 10 mm.
  • Women of childbearing potential (WOCBP) and men must agree to use effective contraception if sexually active. This applies for the time period between signing of the informed consent form and 7 months (for women) o 4 months (for men) after last administration of bortezomib or 6 months after last daratumumab dose, regardless of sex. A woman is considered of childbearing potential, i.e., fertile, following menarche and until becoming postmenopausal unless permanently sterile. Permanent sterilization methods include but are not limited to hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for continuous 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. The investigator or a designated associate is requested to advise the patient how to achieve highly effective birth control method (failure rate of less than 1%) e.g., intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner, and sexual abstinence. The use of condoms by male patients is required unless the female partner is permanently sterile.
  • WOCBP must have two negative pregnancy tests as verified by the study doctor prior to starting study therapy and must agree to undergo monthly pregnancy testing during the course of the study and after end of study therapy if clinically indicated. This applies even if the subject practices complete abstinence from heterosexual contact.
  • Subject understands and voluntarily signs and dates an informed consent form approved by an Independent Ethics Committee (IEC), prior to the initiation of any screening or study-specific procedures
  • Subject must be able to adhere to the study visit schedule and other protocol requirements

Who cannot join

  • Histologic diagnosis different from confirmed plasmablastic lymphoma according to WHO 2017 and/or CD38 expression < 5% of positive cells
  • CNS involvement
  • Patients with known hypersensitivity to the investigational drug or to product components or severe allergic or anaphylactic reactions to humanized products
  • Subject has received any anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy, investigational therapy including targeted small molecule agents within 14 days prior to the first dose of study drug
  • Concomitant Kaposi sarcoma; however, patients with only skin involvement of KS can be included.
  • Subject is:
Show all 25Show fewer
  • Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]. Subjects with resolved infection (i.e., subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen [HBcAb] ± antibodies to hepatitis B surface antigen [HBsAb]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) DNA levels. Those who are PCR positive will be excluded. EXCEPTION: Subjects with serologic findings suggestive of HBV vaccination (HBsAb positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR
  • Known to be seropositive for hepatitis C (except in the setting of a sustained virologic response [SVR], defined as aviremia at least 12 weeks after completion of antiviral therapy)
  • Any history of another cancer during the last 5 years with the exception of non-melanoma skin tumors, in situ cervical carcinoma, or in situ breast cancer treated with curative intent with no history of metastatic disease.
  • Chronic or ongoing active infectious disease requiring systemic treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis or tuberculosis. Drugs for HIV treatment are allowed, as per local investigator prescription.
  • Active ongoing infection from SARS-CoV-2.
  • Screening laboratory values (due to causes different than lymphoma):
  • Absolute neutrophil count (ANC) <1.0 x 109/L (unless secondary to documented marrow involvement by lymphoma)
  • Platelet count <75 x 109/L
  • Hemoglobin < 7.5 g/dL
  • Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) > 3.5 times the upper limit of normal (ULN)
  • Alkaline phosphatase > 3.5 times ULN
  • Bilirubin > 2 times x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin)
  • Serum Creatinine Clearance < 20 ml/h
  • Subject has clinically significant cardiac disease, including:
  • Myocardial infarction within 6 months before date of registration, or unstable or uncontrolled disease/condition related to or affecting cardiac function (e.g., unstable angina, congestive heart failure, New York Heart Association Class III-IV)
  • Cardiac arrhythmia (Common Terminology Criteria for Adverse Events [CTCAE] current version Grade 2 or higher) or clinically significant ECG abnormalities. Screening 12-lead ECG showing a baseline QT interval as corrected by Fridericia's formula (QTcF) > 470 msec
  • Evidence of any other clinically significant uncontrolled condition(s)
  • Significant history of neurologic, psychiatric, endocrinological, metabolic, immunologic, or hepatic disease that would preclude participation in the study or compromise ability to give informed consent
  • Breastfeeding women or women with a positive pregnancy test at screening

Trial locations and contacts

18 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Marina Cesaretti, Dr.ssa contact

059 976 9913

mcesaretti@filinf.it

Lorenza Randi, Dr.ssa contact

0131033153

lrandi@filinf.it

18 sites in 1 country

Italy18 sites, 17 recruiting

  • A.O. Universitaria Ospedali Riuniti - Ospedale Umberto I Di Ancona

    Ancona, Ancona, 60126

    g.gini@ospedaliriuniti.marche.it

    Guido Gini, MD

    Recruiting

  • Aviano - IRCCS Centro di Riferimento Oncologico di Aviano - Divisione di Oncologia e dei Tumori immuto-correlati

    Aviano, Aviano

    mspina@cro.it

    Michele Spina, Dr

    Recruiting

  • A.O. Spedali Civili di Brescia - Ematologia

    Brescia

    Chiara Pagani, MD, chiara.pagani@asst-spedalicivili.it

    Chiara Pagani, MD

    Recruiting

  • Azienda Ospedaliera Universitaria Careggi - Unità funzionale di Ematologia

    Florence, Firenze, 50141

    Luca Nassi, Dott., nassil@aou-careggi.toscana.it

    Luca Nassi, MD

    Recruiting

  • Milano - ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia

    Miano, Italy

    emanuele.ravano@ospedaleniguarda.it

    Emanuele Ravano, Dr

    Recruiting

  • Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia

    Milan

    Andrés Ferreri, andres.ferreri@hsr.it

    Andrés Ferreri, MD

    Recruiting

  • Monza - ASST MONZA Ospedale S. Gerardo - Ematologia

    Monza, Italy

    luisa.verga@libero.it

    Luisa Verga, Dr

    Recruiting

  • Napoli - AORN - Azienda Ospedaliera dei Colli Monald - U.O.C. Oncologia

    Naples, Italy

    Active, not recruiting

  • U.O. Ematologia AO di Padova

    Padova, 35128

    Francesco Piazza, francesco.piazza@unipd.it

    Francesco Piazza

    Recruiting

  • A.O. Universitaria Policlinico Giaccone Di Palermo

    Palermo, Palermo, 90127

    salvatrice.mancuso@unipa.it

    Salvatrice Mancuso, MD

    Not yet recruiting

  • Ematologia IRCCS Policlinico S. Matteo di Pavia

    Pavia

    luca.arcaini@unipv.it

    Luca Arcaini, MD

    Recruiting

  • AO Arcispedale S.Maria Nuova Ematologia

    Reggio Emilia

    Angela Ferrari, Dr.ssa, ferrari.angela@ausl.re.it

    Angela Ferrari, MD

    Recruiting

  • Roma - IRCCS Spallanzani - Servizio di Ematologia in malattie infettive

    Roma, Italy

    michele.bibas@inmi.it

    Michele Bibas, Dr

    Not yet recruiting

  • Roma - Ospedale S. Camillo - Ematologia

    Roma, Italy

    rbattistini@scamilloforlanini.rm.it

    Roberta Battistini, Dr

    Recruiting

  • A.O. S. Maria di Terni - S.C. Oncoematologia

    Terni

    Arcangelo Liso, Prof

    arcangelo.liso@unipg.it

    Not yet recruiting

  • A.O. Universitaria Citta' Della Salute E Della Scienza Di Torino

    Torino, Torino, 10126

    bbotto@cittadellasalute.to.it

    Barbara Botto, MD

    Recruiting

  • Struttura Complessa di Ematologia PO TREVISO

    Treviso, Treviso, 31100

    Piero Maria Stefani, MD, pieromaria.stefani@aulss2.veneto.it

    Piero Maria Stefani, MD

    Recruiting

  • AOU Integrata di Verona - U.O. Ematologia

    Verona, Verona, 37134

    Francesca Maria Quaglia, Dott.ssa, francescamaria.quaglia@gmail.com

    Francesca Maria Quaglia, Dott.ssa

    Recruiting

Other trials in Italy

About this study

Official title: An Open Label, Phase 2 Study to Evaluate Activity and Safety of Daratumumab in Combination With Bortezomib and Dexamethasone in Patients With Relapsed or Refractory Plasmablastic Lymphoma (DALYA Trial)

It is an open-label, multicenter, phase II, single arm trial to Evaluate Activity and Safety of Daratumumab in combination with Bortezomib and Dexamethasone in patients about 28 patients with Relapsed or Refractory Plasmablastic lymphoma.

Read the detailed description

This is an open-label, multicenter, phase II, single arm trial. Patients will be recruited over 18 months in 19 FIL centers and it is expected that a total of 28 patients will start treatment. Analysis of the primary endpoint of the study is planned approximately after 12 months from the enrollment of the last patient, regardless of the response to protocol treatment of this patient. The total duration of the study is 60 months (~5 years).

Patients will be enrolled based on the local diagnosis and the local assessment of CD38 expression ≥ 5%. The screening phase of the study includes baseline assessments according to local practice and those required by the study.

Samples coming from the most recent biopsy, and if available also those used for the first diagnosis, are to be collected and sent afterwards, upon request of the FIL Offices, to one of the three FIL designed central laboratories. Central diagnosis review and CD38 assessment will be performed during or at the end of the study conductance; there's no need to wait for central results to start protocol treatment.

Protocol treatment consists of an induction phase planning one course (cycle 1) of daratumumab sc as single agent followed by 8 courses (cycles 2-9) of daratumumab sc in combination with bortezomib sc and dexamethasone (DVd regimen).

Patients achieving at least a SD after induction will be addressed to the maintenance phase, planning a maximum of 6 cycles (cycles 10-15) of daratumumab sc as single agent.

Induction cycles will be administered every 21 days, while maintenance cycles will be administered every 28 days.

Treatment with DVd or daratumumab single agent will be discontinued before completion of planned cycles in case of disease progression, unacceptable toxicity, withdrawal of consent and/or the investigator determines that further therapy is not in the patient best interest (e.g., due to non-compliance, toxicity, etc.). Adverse events according to CTCAE will be monitored from the first dose of induction treatment, throughout maintenance phase and for 30 days after the last dose of protocol treatment with the study drug or 30 days after the last dose of drug in case of early discontinuation from any cause.

Keywords
Relapsed, Refractory, Plasmablastic, lymphoma, PBL, Daratumumab, Bortezomib, Dexamethasone
Medical subject headings
Plasmablastic Lymphoma, Recurrence, Lymphoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • DaratumumabDrug

    Also called Daratumumab sc

    Induction phase planning one course (cycle 1) of daratumumab as single agent followed by 8 courses (cycles 2-9) of daratumumab in combination with bortezomib and dexamethasone (DVd regimen).

    Patients achieving at least a SD after induction will be addressed to the maintenance phase, planning a maximum of 6 cycles (cycles 10-15) of daratumumab as single agent.

  • BortezomibDrug

    Also called Bortezomib sc

    Induction phase planning one course (cycle 1) of daratumumab as single agent followed by 8 courses (cycles 2-9) of daratumumab in combination with bortezomib and dexamethasone (DVd regimen).

    Patients achieving at least a SD after induction will be addressed to the maintenance phase, planning a maximum of 6 cycles (cycles 10-15) of daratumumab as single agent.

  • DexamethasoneDrug

    Also called Dexamethasone os

    Induction phase planning one course (cycle 1) of daratumumab as single agent followed by 8 courses (cycles 2-9) of daratumumab in combination with bortezomib and dexamethasone (DVd regimen).

    Patients achieving at least a SD after induction will be addressed to the maintenance phase, planning a maximum of 6 cycles (cycles 10-15) of daratumumab as single agent.

Study groups in NCT04915248
Study groupRoleWhat they receive
All patients registered in the DALYA trialExperimentalTreatment consists of an induction phase (every 21 days) planning one course (cycle 1) of daratumumab as single agent followed by 8 courses (cycles 2-9) of daratumumab in combination with bortezomib and dexamethasone (DVd regimen). Patients achieving at least a SD after induction will be addressed to the maintenance phase (every 28 days), planning a maximum of 6 cycles (cycles 10-15) of daratumumab as single agent until disease progression, unacceptable toxicity, withdrawal of consent and/or the investigator decision.
Receives: Drug: Daratumumab; Drug: Bortezomib; Drug: Dexamethasone

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Overall response rate (ORR)

    Response assessment will be done at each restaging. The best overall response will be defined as the best response between the date of beginning of therapy and the last response evaluation. Patients without response assessment (due to whatever reason) will be considered as non-responders.

    Measured: 30 months

Secondary outcomes (7)

  1. Progression-free survival (PFS)

    From the date of starting therapy and the date of disease progression, relapse or death from any cause. Responding patients according to the Lugano classification response Criteria and patients who are lost to follow-up will be censored at their last assessment date.

    Measured: 30 months

  2. Overall survival (OS)

    From the date of starting therapy and the date of death from any cause. Patients alive and those who are lost to follow-up at the time of the final analysis will be censored at the date of the last contact.

    Measured: 30 months

  3. Duration of response (DOR)

    For all patients who achieved a response (CR or PR) according to Response Criteria for NHL with PET (Lugano 2014) and it is measured from the date when criteria for response are met (CR or PR) until the date of progression (including death due to progression) or relapse. Patients without relapse or progression or with death from other cause than progression will be censored at their last assessment date.

    Measured: 30 months

  4. Number of participants with treatment-related adverse events as assessed by current version of CTCAE.

    The safety of daratumumab as single agent and in combination with bortezomib/dexamethasone will be assessed in all patients who have received at least one dose of study medication. Rates of adverse events and of serious adverse events will be will be presented with two sided 95% confidence intervals.

    Measured: 30 months

  5. Rate of Complete Remission (CRR)

    Comparison of ORR and CRR before and after maintenance, and by evaluation of rate of conversion of SD to PR and of SD/PR to CR with daratumumab maintenance.

    Measured: 30 months

  6. Relationship between CD38 expression on lymphoma cells, assessed by immunohistochemistry, and the response rate.

    The extent of CD38 expression evaluated by immunochemistry on the diagnostic biopsy-tissue will be correlated with response measured according to the Lugano 2014 criteria at various timepoints: after induction cycle 1, after induction cycles 3, 6 and 9 (end of induction, EOI); after maintenance cycles 12 and 15 (end of treatment, EOT). correlated with response measured according to the Lugano 2014 criteria at various endpoints.

    Measured: 30 months

  7. Impact of daratumumab and bortezomib treatment on biological cell profiles.

    The impact of daratumumab and bortezomib treatment in immune activation (CD38, CD25, HLA-DR), T cell differentiation (naïve, central memory, effector memory and terminal effector memory T cell subset) and on circulating myeloid-derived suppressor cells (MDSC) as well as Treg will be evaluated by multiparametric flow cytometry (84 multiple staining). Peripheral blood samples will be collected in different timepoints: before treatment start; after cycle 1; after cycle 3 and at EOT.

    Measured: 30 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Jun 2021
  2. Study start11 Jul 2022
  3. Primary completion1 Jul 2027 (estimated)
  4. Study completion1 Jul 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
28 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04915248
Sponsor's protocol ID
FIL_DALYA
Acronym
FIL_DALYA
Status last verified
Sep 2026
First submitted
14 May 2021
Last updated
9 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Daratumumab, Bortezomib and Dexamethasone in people with Plasmablastic Lymphoma, run by Fondazione Italiana Linfomi - ETS at 18 sites in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 15 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 9 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 18 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Marina Cesaretti, Dr.ssa (059 976 9913, mcesaretti@filinf.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Overall response rate (ORR) (time frame: 30 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04915248.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in